Las Vegas, NV -- (SBWIRE) -- 09/21/2013 -- PennyStockEarnings Team record for picking gainers is one of the best in the business, and our followers continue to make substantial profits – even in bear markets. Our Team includes top analysts and use level II screeners to get you the information you need to make intelligent decisions for trading penny stocks. Our Today’s Focus is On: Celsion Corporation (NASDAQ:CLSN), PDL BioPharma Inc. (NASDAQ:PDLI), Idenix Pharmaceuticals Inc (NASDAQ:IDIX), Nektar Therapeutics (NASDAQ:NKTR)
Corporation (NASDAQ:CLSN) climbed +2.52% and closed at $1.22 in the last trading session with the overall traded volume of 1.85 million shares, more versus the average volume of 1.93 million shares. Its 52 weeks high price was $9.44 and suffered lowest price of $0.75 in the same period.
It has market cap of $74.62 million while its total outstanding shares are 61.16 million. Its stock’s 3 months performance stands at -8.27%. Celsion Corporation, an oncology drug development company, focuses on the development and commercialization of targeted chemotherapeutic oncology drugs based on its proprietary heat-activated liposomal technology.
What was the Moving Force behind CLSN On Bullish Run? Read This Research Report
PDL BioPharma Inc. (NASDAQ:PDLI) declined -0.43% with the closing price of $8.05. The overall volume in the last trading session was 1.87 million shares. Its fifty two week range was $6.50-$8.48. The total market capitalization remained $1.13 billion.
The stock gained +13.47% in this year and reported the loss of +3.01 in the last 5 days. In its share capital, the company has 140.04 million outstanding shares. PDL BioPharma, Inc. engages in intellectual property asset management and patent portfolio and related assets investment activities.
Will PDLI Get Buyers Even After The Recent Rally? Find Out Here
Idenix Pharmaceuticals Inc (NASDAQ:IDIX) decreased -1.58% to close at $5.60 in the last trading session and its total traded volume was 2.41 million shares, beating the average volume of 914,500. The company has market cap of $750.19 million.
The stock has positive year-to-date performance of +25.28% while its quarterly performance remained +9.16%. Idenix Pharmaceuticals, Inc., a biopharmaceutical company, together with its subsidiaries, engages in the discovery and development of drugs for the treatment of human viral diseases in the United States and France.
Has IDIX Found The Bottom and Ready To Move Up? Find Out Here
Nektar Therapeutics (NASDAQ:NKTR) moved up +1.16% to closed at $13.96 and its overall volume in the last trading session was 2.16 million shares, beating the average volume of 1.17 million. It has market cap of $1.62 billion while its total outstanding shares are 115.76 million.
The stock gained +97.18% in this year and reported the loss of +3.42% in the last 5 days. Its 3 months performance stands at +31.82%. Nektar Therapeutics, a clinical-stage biopharmaceutical company, engages in developing a pipeline of drug candidates that utilize its PEGylation and polymer conjugate technology platforms.
For How Long NKTR will Fight for Profitability? Read This Trend Analysis report
PennyStockEarnings.com is keen to discover penny stocks with the potential to make short and long-term gains.
PSE Team record for picking gainers is one of the best in the business, and our followers continue to make substantial profits – even in bear markets. Our Team includes top analysts and use level II screeners to get you the information you need to make intelligent decisions for trading penny stocks.
PLEASE NOTE WELL: The employees of PennyStockEarnings.com are not registered as Investment Advisors in any jurisdiction whatsoever. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. Investing in “penny stocks” is highly speculative.
Verify all claims and do your own due diligence on all securities. PennyStockEarnings.com profiles are not a solicitation or recommendation to buy, sell or hold securities. PennyStockEarnings.com is not offering securities for sale. Neither PennyStockEarnings.com nor its owners, operators, affiliates or anyone disseminating information on its behalf is registered as an Investment Advisor under any federal or state law and none of the information provided by PennyStockEarnings.com, its owners, operators, affiliates or anyone disseminating information on its behalf should be construed as investment advice or investment recommendations. PennyStockEarnings.com does not recommend that the securities profiled should be purchased, sold or held.
Read Full Disclaimer Here: http://www.pennystockearnings.com/disclaimer/
Copyright © 2005-2013 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-593-5640 (International)